Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market

Company’s new $50 million funding is the first since its April merger, as competition grows among nation’s contract research organizations (CROs)   Key points: dMed-Clinipace’s raises $50 million in the first funding since its merger to form a CRO specialist with global presence Eased regulations have fueled an influx of money and spate of M&A in China’s increasingly competitive landscape By Richard Barbarossa Fresh off the April merger that created a major new Sino-U.S. clinical oncology contract research organization (CRO), dMed-Clinipace has embarked on a new round of fundraising as…

Read MORE »